Rhizen Pharmaceuticals gets USFDA nod for cancer drug Umbralisib
Rhizen Pharmaceuticals gets USFDA nod for cancer drug Umbralisib February 09, 2021 In a first, Indian scientists develop oral drug for relapsed or refractory MZL, FL In a major breakthrough in cancer treatment, Alembic Pharmaceutical’s co-owned Rhizen Pharmaceuticals has received US drug regulator - US Food and Drug Administration (USFDA)’s approval for novel next generation oral inhibitor of phosphoinositide 3 kinase (PI3K) delta - Umbralisib for treatment of relapsed or refractory marginal zone lymphoma (MZL), follicular lymphoma (FL). Umbralisib will be marketed by Nasdaq-listed TG The...
Source: thehindubusinessline.com